Other recently developed (pre)clinical HAUSP inhibitors (e.g., FT671, XL188, and GNE6640)109–111 will need to be used to establish a portfolio of HAUSP-PTEN axis-targeting drugs for use in future cancer therapies. Here, PTEN is linked to cancer.